{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:08:43Z","timestamp":1784077723799,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40120-024-00600-1","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T09:13:37Z","timestamp":1711962817000},"page":"655-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02291861","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02195700","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01795859","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02198794","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01897896","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Samuel","family":"Frank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Claassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stamler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart A.","family":"Factor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohi","family":"Jimenez-Shahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Barkay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayla","family":"Chaijale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Barash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha-Matti","family":"Savola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Forrest","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"issue":"6","key":"600_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/pcn.12270","volume":"69","author":"PP Lerner","year":"2015","unstructured":"Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69(6):321\u201334.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"600_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1399-0004.2011.01748.x","volume":"80","author":"AK Ho","year":"2011","unstructured":"Ho AK, Hocaoglu MB. Impact of Huntington\u2019s across the entire disease spectrum: the phases and stages of disease from the patient perspective. Clin Genet. 2011;80(3):235\u20139.","journal-title":"Clin Genet"},{"issue":"5","key":"600_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40271-018-0312-x","volume":"11","author":"EM Thorley","year":"2018","unstructured":"Thorley EM, Iyer RG, Wicks P, et al. Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018;11(5):547\u201359.","journal-title":"Patient"},{"key":"600_CR4","doi-asserted-by":"crossref","unstructured":"Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (NY). 2013;3. tre-03-161-4138-4131.","DOI":"10.5334\/tohm.165"},{"issue":"2","key":"600_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ncl.2020.01.004","volume":"38","author":"HH Bashir","year":"2020","unstructured":"Bashir HH, Jankovic J. Treatment of tardive dyskinesia. Neurol Clin. 2020;38(2):379\u201396.","journal-title":"Neurol Clin"},{"key":"600_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2018.02.005","volume":"389","author":"D Savitt","year":"2018","unstructured":"Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35\u201342.","journal-title":"J Neurol Sci"},{"issue":"3","key":"600_CR7","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264-278.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"600_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40120-018-0105-0","volume":"7","author":"KM Ward","year":"2018","unstructured":"Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia\u2014key differences in pathophysiology and clinical management. Neurol Ther. 2018;7(2):233\u201348.","journal-title":"Neurol Ther"},{"key":"600_CR9","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"600_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204\u201316.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"600_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0193-953X(05)70345-2","volume":"20","author":"MS Haddad","year":"1997","unstructured":"Haddad MS, Cummings JL. Huntington\u2019s disease. Psychiatr Clin North Am. 1997;20(4):791\u2013807.","journal-title":"Psychiatr Clin North Am"},{"key":"600_CR12","unstructured":"Austedo. Package insert. Teva Neuroscience, Inc; 2023."},{"issue":"21","key":"600_CR13","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","volume":"88","author":"HH Fernandez","year":"2017","unstructured":"Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003\u201310.","journal-title":"Neurology"},{"issue":"8","key":"600_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","volume":"4","author":"KE Anderson","year":"2017","unstructured":"Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase\u00a03 trial. Lancet Psychiatry. 2017;4(8):595\u2013604.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"600_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40\u201350.","journal-title":"JAMA"},{"key":"600_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.773999","volume":"13","author":"RA Hauser","year":"2022","unstructured":"Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13: 773999.","journal-title":"Front Neurol"},{"issue":"11","key":"600_CR17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","volume":"36","author":"S Frank","year":"2022","unstructured":"Frank S, Testa C, Edmondson MC, et al. The safety of deutetrabenazine for chorea in Huntington disease: an open-label extension study. CNS Drugs. 2022;36(11):1207\u201316.","journal-title":"CNS Drugs"},{"issue":"12","key":"600_CR18","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","volume":"21","author":"K Horv\u00e1th","year":"2015","unstructured":"Horv\u00e1th K, Aschermann Z, \u00c1cs P, et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord. 2015;21(12):1421\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"600_CR19","unstructured":"Ingrezza. Package insert. Neurocrine Biosciences, Inc; 2021."},{"key":"600_CR20","unstructured":"Xenazine. Package insert. Lundbeck; 2020."},{"issue":"3","key":"600_CR21","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1212\/WNL.0000000000005817","volume":"91","author":"JL Schultz","year":"2018","unstructured":"Schultz JL, Killoran A, Nopoulos PC, Chabal CC, Moser DJ, Kamholz JA. Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology. 2018;91(3):e202\u2013207.","journal-title":"Neurology"},{"key":"600_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1471-2377-9-62","volume":"9","author":"S Frank","year":"2009","unstructured":"Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. BMC Neurol. 2009;9:62.","journal-title":"BMC Neurol"}],"updated-by":[{"DOI":"10.1007\/s40120-024-00660-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00600-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T16:23:21Z","timestamp":1726158201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00600-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00600-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40120-024-00660-3","asserted-by":"object"}]},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"19 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-024-00660-3","URL":"https:\/\/doi.org\/10.1007\/s40120-024-00660-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samuel Frank is principal investigator of First-HD and ARC-HD (Teva), consultant for Novartis, Sage Therapeutics, and uniQure, and has received research support from Cure Huntington\u2019s Disease\u00a0Initiative Foundation, Huntington\u2019s Disease Society of America, the Huntington Study Group, Neurocrine, Roche\/Genentech, and Triplet Therapeutics. Karen E. Anderson is global principal\/co-principal investigator of AIM-TD and ARM-TD (Teva Pharmaceuticals; funds paid directly to her institution, Georgetown University), North American study co-principal investigator of LEGATO-HD (Teva), site principal investigator of Pride-HD, First-HD, and ARC-HD (Teva), ENROLL-HD (Cure Huntington\u2019s Disease\u00a0Initiative Foundation), Vaccinex, and site investigator for Generation HD studies (Roche Biogen). She is a consultant for NeuroNEXT 105 study (Azevan) and scientific advisor for Azevan, Biogen, Cure Huntington\u2019s Disease\u00a0Initiative Foundation, Novartis, Prana, and Roche. She has received salary support from The Griffin Foundation and Honoraria from Vindico Medical Education. Hubert H. Fernandez has received honoraria from AbbVie, Biogen, Carling Communications, GE Health Care, inVentiv, International Parkinson and Movement Disorders Society, Kyowa Hakko Kirin, Lundbeck, Medscape (speaker in CME events), Merz Pharmaceuticals, Pfizer (as a consultant), Prime Education, Sunovion, and Voyager Therapeutics. He has been provided grant and research support by AbbVie, Acadia, Biotie\/Acorda, Civitas, Kyowa\/ProStrakan, Michael J. Fox Foundation, Movement Disorders Society, National Institute of Health\/National Institute of Neurological Disorders and Stroke, Parkinson Study Group, Rhythm Pharmaceuticals, Synosia, Teva Pharmaceuticals. He has received royalties from Demos Publishing (serving as a book author\/editor) and contractual services with The Cleveland Clinic via a contract with Teva for Dr Fernandez\u2019s role as co-principal investigator in SD-809 tardive dyskinesia global studies. Dr Fernandez also serves as a member of the publication committee for Acorda, but does not receive any personal compensation for this. He has received a stipend from the International Parkinson and Movement Disorders Society for serving as medical editor for the MDS website. Robert A. Hauser has served as a consultant with AbbVie, Academy for Continued Healthcare Learning, Acorda, Adamas Pharmaceuticals, AstraZeneca, Back Bay Life Science, Biotie, ClearView Healthcare Partners, ClinicalMind Medical and Therapeutic Communications, Cowen and Company, Cynapsus, eResearch Technology, Expert Connect, Gerson Lehrman Group, Guidepoint Global, Health Advances, HealthLogiX, Impax Laboratories, Kyowa Kirin Pharmaceutical Development, LCN Consulting, LifeMax, Lilly, Lundbeck, Michael J. Fox Foundation, National Institutes of Health, National Parkinson Foundation, Neurocrine, Neuropore, Outcomes Insights, PeerView Press, Pfizer, Pharma Two B Ltd., Prexton, Projects in Knowledge, Putnam Associates, Quintiles, RMEI Medical Education for Better Outcomes, Sarepta, Sunovion, Teva Pharmaceuticals, US WorldMeds, and Vista Research. Daniel O. Claassen has received research support from Griffin Foundation, Huntington\u2019s Disease Society of America, Michael J. Fox Foundation, National Institute of Neurological Disorders and Stroke, and National Institute on Aging, and grant support from AbbVie, Acadia, Biogen, Bristol Myers Squibb, Cerecor, Jazz Pharmaceuticals, Lilly, Lundbeck, Teva Pharmaceuticals, Vaccinex, and Wave Life Sciences. Dr Claassen is a consultant\/scientific advisor for Acadia, Adamas Pharmaceuticals, Alterity, Lundbeck, Neurocrine, Teva Pharmaceuticals, and Wave Life Sciences. David Stamler is a former employee of Teva Pharmaceuticals. He receives salary and benefits from Auspex Pharmaceuticals. Patents pending: US20160346270, US20160287574. Stewart A. Factor has received honoraria from Acorda, Biogen, CereSpir, Neurocrine, Lundbeck, Teva Pharmaceuticals, Avanir, UCB, US WorldMeds, Sunovion, and Adamas Pharmaceuticals. He has received research support from Biohaven, Boston Scientific, Impax, Ipsen, Jazz Pharmaceuticals, Lilly, Medtronic, National Institutes of Health (U10 NS077366), Neurocrine, Parkinson Foundation, Sun Pharmaceuticals Advanced Research Company, Voyager Therapeutics, Auspex, US WorldMeds, Pharm-Olam, Cynapsus\/Sunovion, Vaccinex, Solstice, Cure Huntington\u2019s Disease\u00a0Initiative Foundation, Michael J. Fox Foundation. He has received royalties from Demos, Blackwell Futura, Springer (textbooks), Uptodate. He has other conflicts of interest with Signant Health (Bracket Global LLC) and CNS Ratings. Joohi Jimenez-Shahed has received consulting fees from AbbVie, Blue Rock Therapeutics, Bracket Global, Medtronic, Nuvelution, Photopharmics, St. Jude Medical, Teva Pharmaceuticals. Hadas Barkay is an employee of Teva Pharmaceutical Industries Ltd. Amanda Wilhelm and Jessica K. Alexander are former employees of Teva Branded Pharmaceutical Products R&D, Inc. Nayla Chaijale, Steve Barash, Mark Forrest Gordon, and Maria Chen are employees of Teva Branded Pharmaceutical Products R&D, Inc. Juha-Matti Savola is a former employee of Teva Pharmaceuticals International GmbH, Basel, Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and did not require any approvals or informed consent; approval and consent were obtained with conduct of the initial studies, which were in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}